Navigation Links
NeoStem Appoints Deloitte & Touche as New Independent Registered Public Accounting Firm

NEW YORK, March 16 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. ( NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, announced today the appointment of Deloitte & Touche LLP ("Deloitte & Touche") as the Company's independent registered public accountant for fiscal year 2010.

The decision to change independent registered public accounting firms was recommended and approved by NeoStem's Audit Committee of the board of directors on March 11. NeoStem's engagement with current auditor Holtz Rubenstein Reminick LLP ("HRR") will end following completion of the 2009 audit of the Company's financial statements and filing of the Form 10-K. HRR's audit of NeoStem's 2007 and 2008 financial statements did not contain any adverse opinions or disclaimer of opinion, and there have been no disagreements between the Company and HRR on any matter regarding accounting principles or practices, financial statement disclosure or auditing scope or procedure during fiscal 2007, fiscal 2008 and the subsequent interim period through March 11, 2010.

"Over the past year, NeoStem has evolved into a sophisticated multinational operation with multiple businesses in the U.S. and China and has more complex financial and accounting needs, which we believe are best serviced by a Big Four accounting firm, such as Deloitte & Touche," said Robin Smith, M.D., NeoStem's CEO and Chairman of the board of directors. "We thank HRR for their adept service in recent years and look forward to working with Deloitte & Touche as the Company continues to grow and increase shareholder value."

About NeoStem, Inc.

NeoStem, Inc. is engaged in the development of stem cell-based therapies, pursuit of anti-aging initiatives and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company also has licensed various stem cell technologies, including a worldwide exclusive license to VSEL(TM) technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit: .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to continued growth of the Company, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Registration Statement on Form S-1 filed with the Securities and Exchange Commission on as well as periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

    For more information, please contact:

    NeoStem, Inc.
     Robin Smith, CEO
     Phone: +1-212-584-4174

    CCG Investor Relations, Inc.
     Lei Huang, Account Manager
     Phone: +1-646-833-3417

     Crocker Coulson, President
     Phone: +1-646-213-1915

SOURCE NeoStem, Inc.

Back to top



SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. NeoStem Announces Presentation Time Change at Roth Capital Partners 22nd Annual OC Growth Stock Conference
2. NeoStem Enters into SRA with University of Michigan; Funding from NIH Stem Cell Research Grant
3. NeoStem Prices Public Offering of 5,000,000 Shares of Common Stock
4. Busy Southwestern Orthopedic Practice Joins the NeoStem Stem Cell Collection Network
5. NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company
6. United States Securities and Exchange Commission Declares Effective Registration Statement for NeoStems Acquisition of China Biopharmaceuticals Holdings, Inc. and a Controlling Interest in Leading Chinese Pharmaceutical Company; Meeting of Each Com
7. NeoStem, Inc. Awarded NIH Research and Research Infrastructure Grand Opportunities Grant
8. NeoStem CEO to Participate in 2009 World Stem Cell Summit on September 23rd
9. NeoStem, Inc. is Certified by the State of New York as a Qualified Emerging Technology Company and Notifies Investors of Possible Tax Credit of up to 20%
10. NeoStem, Inc. Appoints Leading Chinese Medical Official to Its Advisory Board
11. NeoStem Featured on CBS2 News; Success of Licensed Stem Cell Treatments Shown for Arthritis and Orthopedic Problems; Procedure to be Used by NeoStem Affiliate in China
Post Your Comments:
(Date:11/24/2015)... Nev. , Nov. 24, 2015  PDL BioPharma, Inc. ... P. McLaughlin , the company,s president and chief executive officer, ... Healthcare Conference next week in New York City ... occur on Tuesday, December 1, 2015 at 9:30 a.m. EST. ... Please connect to the website at least 15 minutes prior ...
(Date:11/24/2015)... ... ... Laboratories is pleased to announce that it has completed construction on a new ... 61, USP 62 and USP 51 testing specific to raw materials and will enable ... by one supplier. Management has formally announced that the facility will be ...
(Date:11/23/2015)... CHICAGO , Nov. 24, 2015 Women with ... screening CT exams face a higher risk of lung cancer ... being presented next week at the annual meeting of the ... --> --> Lung ... are classified as solid or subsolid based on their appearance ...
(Date:11/23/2015)... KONG, Nov. 23, 2015 China Cord Blood ... China,s leading provider of cord blood collection, laboratory testing, ... today announced its preliminary unaudited financial results for the ... ended September 30, 2015. --> ... , Revenues for the second quarter of fiscal ...
Breaking Biology Technology:
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... health pioneer, Joseph C. Kvedar , MD, describes ... wellness, and the business opportunities that arise from it ... Healthy Things . Long before health and wellness ... vice president, Connected Health, Partners HealthCare, was creating a ... the hospital or doctor,s office into the day-to-day lives ...
(Date:10/27/2015)... SAN JOSE, Calif. , Oct. 27, 2015 /PRNewswire/ ... human interface solutions, today announced that Google has adopted ... family of touch controller solutions to power its newest ... Nexus 6P by Huawei. --> ... ecosystem partners like Google to provide strategic collaboration in ...
Breaking Biology News(10 mins):